Form 4: Exelixis CSO Dana Aftab Reports Stock Transactions

Dana Aftab, CSO/EVP of Discovery & Translational Research at Exelixis, reports the acquisition and disposal of common stock, including shares from the employee stock purchase plan and holdings in a 401(k) plan.

Summary

• Dana Aftab, CSO/EVP of Discovery & Translational Research at Exelixis, filed a Form 4 detailing changes in beneficial ownership of Exelixis stock.
• The report indicates a transaction date of May 1, 2025.
• Aftab disposed of 1,508 shares of common stock at a price of $39.
• Aftab directly owns 693,181 shares of common stock, including shares from restricted stock units (RSUs) and performance-based restricted stock units (PSUs).
• Aftab indirectly owns 5,835 shares through the Exelixis, Inc. 401(k) Plan as of April 30, 2025.
• The filing was signed on May 5, 2025, by Nina Ayer, Attorney in Fact.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's common for executives to have holdings in company stock through various compensation plans.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider trading activities.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transaction, Exelixis, Aftab, Equity